Tesaro (TSRO) PT Raised to $139 at Wedbush
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Tesaro (TSRO) PT Raised to $120 at Baird
October 10, 2016 7:51 AM EDTBaird analyst Michael Ulz reiterated an Outperform rating and raised his price target on Tesaro (NASDAQ: TSRO) to $120.00 (from $105.00) with full niraparib data better than expected.
Ulz commented, "Over the weekend, detailed data from the Phase 3 NOVA study of niraparib in 2L+... More
Tesaro (TSRO) PT Raised to $128 at RBC Capital
October 10, 2016 7:27 AM EDTRBC Capital analyst Adnan Butt reiterated an Outperform rating and raised its price target on Tesaro (NASDAQ: TSRO) to $128.00 (from $122.00) following NOVA Phase 3 trial details.
Butt commented, "Details show biomarker/HRD-positive benefit is not driven by somatic BRCA patients alone, biomarker/HRD-negative... More
Tesaro (TSRO) PT Raised to $122 at Credit Suisse
October 10, 2016 7:25 AM EDTCredit Suisse analyst Alethia Young reiterated an Outperform rating and boosted her price target on Tesaro (NASDAQ: TSRO) to $122.00 (from $90.00) saying the big takeaway on Tesaro data is that it works broadly in all 2L ovarian populations and safety looks solid. They also think the robustness of this data bodes well from... More
TESARO (TSRO) Presents Statistically Significant Phase 3 ENGOT-OV16/NOVA Trial Results at ESMO
October 10, 2016 6:40 AM EDTOver the weekend, TESARO, Inc. (NASDAQ: TSRO) and ENGOT, the European Network for Gynaecological Oncological Trial groups, today announced the presentation of the niraparib Phase 3 ENGOT-OV16/NOVA clinical trial results at the ESMO 2016 Congress, the congress of the European Society for Medical Oncology (ESMO), by Dr. Mansoor Raza Mirza, M.D., Medical Director of the Nordic Society of Gynecologic Oncology (NSGO) and principal investigator on the ENGOT-OV16/NOVA trial. These data were discussed during the ESMO press briefing in Copenhagen as part of the congress, and were simultaneously published online in the New... More
Tesaro (TSRO) PT Raised to $115 at Leerink Following Full Results of Ph 3 NOVA Trial
October 10, 2016 6:34 AM EDTLeerink Partners analyst Seamus Fernandez reiterated an Outperform rating and raised its price target on Tesaro (NASDAQ: TSRO) to $115.00 (from $108.00) after full results of the Ph 3 NOVA trial (niraparib as 2L maintenance for ovarian cancer) presented in a Presidential Session at ESMO and... More
